Benefits
Stress and anxiety marker support in healthy adults
In a randomized controlled trial in healthy adults, Lpc-37 supplementation was associated with reduced perceived stress vs placebo, with the strongest signals in pre-specified subgroups based on baseline chronic stress and sex. Positioning is for stress-resilience support in healthy adults rather than for clinical anxiety disorders.
Gut-brain axis exploration
Lpc-37 sits within the emerging ‘psychobiotic’ category of probiotic strains explored for gut–brain axis effects on stress, mood, and sleep markers. The mechanism is hypothesized to involve gut-mediated regulation of HPA-axis tone and inflammatory signaling.
Strain-specific evidence base
Distinct strain identifier and characterized clinical outcomes make Lpc-37 a strain-level psychobiotic candidate rather than a generic L. paracasei. Branded formulations carrying the Lpc-37® designation provide a defined product specification for clinical use.
Adjunct to daily probiotic strategies
Lpc-37 can be combined with other characterized probiotic strains in multi-strain formulations targeting both gut and stress endpoints, fitting into broader daily probiotic and gut-health support strategies.
Mechanism of action
Gut–brain axis signaling
Specific probiotic strains are hypothesized to influence the gut–brain axis via vagal afferents, modulation of gut-derived neurotransmitters and short-chain fatty acids, and immune signaling. Lpc-37 is being evaluated within this framework as a stress-support psychobiotic.
HPA-axis modulation
Psychobiotic candidates including Lpc-37 are studied for their potential to attenuate hypothalamic-pituitary-adrenal axis reactivity to stress, supporting normalization of cortisol response in some subgroups. Direct mechanistic data in humans is still being characterized.
Intestinal barrier and immune signaling
Like other L. paracasei strains, Lpc-37 may support intestinal barrier function and modulate mucosal immune signaling, with downstream effects on systemic inflammatory tone that has been linked to mood and stress markers in observational research.
Clinical trials
Randomized, double-blind, placebo-controlled, parallel-group trial of Lacticaseibacillus paracasei Lpc-37 (1.75×10¹⁰ CFU/day) vs placebo in 120 healthy adults aged 18-45 for 5 weeks. Outcomes: Perceived Stress Scale, Trier Social Stress Test response, cortisol, heart rate, sleep, well-being. Published in Neurobiology of Stress.
120 healthy adults aged 18-45 with subjective stress; 5-week intervention.
Primary endpoint (Perceived Stress Scale change) was not statistically significant overall. Pre-specified subgroup and secondary analyses showed reduced perceived stress in Lpc-37 vs placebo in participants with higher baseline chronic stress, alongside selective effects on heart rate and well-being measures. Supports modest stress-resilience signal in healthy adults; not a treatment claim.
Strain identification and product specification work supporting the clinical use of Lpc-37 as a defined Lacticaseibacillus paracasei strain. Used in conjunction with Sisu and related trials to position Lpc-37 within the broader psychobiotic category.
Strain-level characterization; supports clinical-trial product identification rather than direct clinical outcome.
Lpc-37 has a defined strain identifier and standardized product specification, providing a basis for reproducible clinical evaluation and commercial differentiation from generic L. paracasei products.